To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:2 Issue:9 Number:6 ISSN#:2564-2537
Author Verified
ACE Report #5315
Ace Report Cover Osteoarthritis

Combined teriparatide and denosumab treatment increased BMD in postmenopausal osteoporosis

How to Cite

OrthoEvidence. Combined teriparatide and denosumab treatment increased BMD in postmenopausal osteoporosis. ACE Report. 2013;2(9):6. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15

Contributing Authors:
JN Tsai AV Uihlein H Lee R Kumbhani E Siwila-Sackman EA McKay SA Burnett-Bowie RM Neer BZ Leder

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


One hundred women with osteoporosis were evaluated to compare the efficacy of teriparatide, denosumab, or combined treatment of both drugs on spinal, femoral, and hip bone mineral density (BMD) at 12 months. They were randomized either to daily 20 ug teriparatide daily, 60 mg denosumab every 6 months, or both. At the final follow up, the combination group had increased significantly in posterioran...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.